Clinical Trials | October 27, 2021
Dr Lal PathLabs to acquire Suburban Diagnostics for Rs 925 crore
Dr Lal PathLabs revenue contribution from west India to go up from 10% to 24% post-acquisition basis FY21
Dr Lal PathLabs revenue contribution from west India to go up from 10% to 24% post-acquisition basis FY21
The collaboration aims to deliver greater insights to the oncology fraternity, predict patient therapy responses and enable therapy selection resulting in optimal treatment outcomes.
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
This unique record was made possible by collating hard copies of the books in a structured manner
The implant is surgically inserted into the eye during a one-time, outpatient procedure and refilled every six months
With the launch of QurOne, the brand aims to redefine healthcare in the country with seamless, hassle-free patient care and hyper-coordinated workflows
The company is continuing with the evaluation of canakinumab in lung cancer, and is applying findings to the overall lung cancer development plan
It’s the company’s fourth manufacturing site worldwide. Others are located in the US, UK and China
This strategic collaboration will enable continued innovation in cancer care
Subscribe To Our Newsletter & Stay Updated
